- Delivery Method:
- Via Certified Email
Recipient NameThomas E. Silvonek
- Dorneyville Pharmacy
3330 Hamilton Blvd.
Allentown, PA 18103-4537
- Issuing Office:
- Office of Pharmaceutical Quality Operations, Division I
Dear Mr. Silvonek:
The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (17-PHI-05, February 7, 2017). Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.
You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Stephanie Durso, Director Compliance Branch
Office of Pharmaceutical Quality Operations, Division I